The growing pipeline of biologicsthat can be produced in microbial systems, such as antibody fragments andplasmid-based therapies, is anticipated to offer lucrative opportunities toservice providers serving this niche, but growing market segment
London
Roots Analysis has announced the addition of the “MicrobialContract Biomanufacturing Market, 2020-2030” report to its listof offerings.
Despite mammaliancell cultures being the preferred manufacturing approach for biologics, recentadvances in microbial fermentation haveenabled the development of versatile biomanufacturing systems, which are bothrobust and cost friendly. Presently, a number of service provider companiesclaim to offer end-to-end solutions, ranging from product development tocommercial production, for microbial biologics. Given the obvious advantages ofoutsourcing, drug developers are likely to continue relying on contract serviceproviders for various aspects of their respective microbial biologic developmentprograms.
Toorder this 320+ page report, which features 150+ figures and 150+ tables,please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Key Market Insights
Over115 CMOs claim to offer manufacturing services for microbial biologics
The microbialcontract biomanufacturing market is highly fragmented, featuring a mix ofsmall, mid-sized, large and very large players. It is worth mentioning thatmore than 50% of CMOs mentioned in the report, have the necessary capabilitiesto manufacture biologics across all scales of operation (preclinical,clinical and commercial).
Presently, more than 70% of service providers use bacterialexpression systems
Recently, a number ofmicrobial biologics manufacturers are shifting to yeast-based productionsystems. It is also worth highlighting that close to 30% of CMOs, identified inthis research, claim to have the required capabilities to manufacture biologicsusing both bacterial and yeast-based systems.
Europe is currently regarded as a key manufacturing hub formicrobial biologics
There are more than150 manufacturing facilities, with microbial fermentation capabilities, worldwide;of these, 43% are in Europe, followed by North America (31%). On the otherhand, prominent regions in the Asia Pacific and Middle East, where microbialbiologics are manufactured, include (in decreasing order of number of residentmanufacturing facilities) China, India, Japan, Australia and Israel.
Severalpartnerships were established in this domain, during the period 2016-2020
Majorityof the deals recorded in the report, were established in 2019. Further, a largenumber (~25%) of the partnerships were observed to be focused on the productionof microbial biologics; this is followedby process development and manufacturing agreements (20%).
Further,multiple expansion initiatives were undertaken by CMOs, since 2016
More than 30% ofexpansion projects over the last few years were focused on the establishment ofnew facilities, followed by those involving the expansion of existingmanufacturing facilities (28%). Further, 50% of the expansion initiatives mentionedin the report, were in undertaken by stakeholder companies in Europe, followedNorth America (39%).
Big pharma playershave also been active in this upcoming field
Around 60% of theinitiatives undertaken by big pharma were reported in the period 2016-2020. Ofthese, 57% involved the establishment of strategic partnerships with otherindustry stakeholders. It is worth highlighting that, in terms of type of biologic, close to 49%of these initiatives were focused on recombinant proteins.
NorthAmerica and Europe are anticipated to capture over 80% share (in terms ofservice revenues) of the market, by 2030
At present, more than60% of the total revenues are generated from commercialized microbialbiologics, and this trend is unlikely to change significantly in short tomid-term. Further, it is worth mentioning that the contract biomanufacturing marketfor microbial biologics in the Middle East and North Africa is anticipated togrow at a relatively faster rate (10.3%), followed by Asia Pacific (9%).
To request a sample copy / brochure of this report, please visitthis - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market/request-sample.html
KeyQuestions Answered
§ Who are the leading CMOs engaged in the production ofmicrobial biologics?
§ What are the preferred microbial systems for thedevelopment and manufacturing of biologics?
§ Which are the key microbial fermentation technologyplatforms currently available in the market?
§ What kind of partnership models are commonly adopted bystakeholders in this industry?
§ What are the various initiatives undertaken by the bigpharma players engaged in this domain?
§ What are the key factors influencing the make (manufacturein-house) versus buy (outsource) decision related to the production of microbialbiologics?
§ What are the key trends within the microbial contractbiomanufacturing market?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
The USD 9.3 billion (by 2030) financial opportunitywithin the microbial contract biomanufacturing market has been analyzed acrossthe following segments:
§ Typeof Product
§ API
§ FDF
§ Typeof Biologic
§ Proteins
§ Enzymes
§ Growth Hormones
§ Antibody based Drugs
§ Others (plasmid DNA, probiotics, microbiome-basedbiologics)
§ Type of Microbial Expression System
§ Bacteria
§ Yeast
§ Others (Algae and fungi)
§ Scaleof Operation
§ Commercial
§ Preclinical/ Clinical
§ Typeof End User
§ SmallCompanies
§ Mid-sizedCompanies
§ Large/ Very Large Companies
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ AsiaPacific
§ MiddleEast and North Africa
§ LatinAmerica
The report featuresinputs from eminent industry stakeholders, according to whom, currently, over50% operations related to both API and FDF manufacturing of microbial biologicsare outsourced to third party service providers. The report includes detailedtranscripts of discussions held with the following experts:
The research coversprofiles of key players (listed below); each profile features anoverview of the company, information related to its microbial manufacturingfocused service portfolio, production facilities and capabilities, and aninformed future outlook.
§ AGC Biologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ Northway Biotechpharma
§ Ology Bioservices
§ Porton Biopharma
§ Stelis Biopharma
For additionaldetails, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html oremail sales@rootsanalysis.com
You may also beinterested in the following titles:
1. DrugRepurposing Service Providers Market, 2020 – 2030
2. AntibodyDiscovery Services and Platforms Market (3rd Edition), 2020-2030
3. LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active PharmaceuticalIngredients and Finished Dosage Forms, 2020 - 2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in the bio-pharmaceuticalindustry. The in-depth research, analysis and insights are driven by anexperienced leadership team which has gained many years of significantexperience in this sector. If you’d like help with your growing business needs,get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter- https://twitter.com/RootsAnalysis
